Scholars Central

Research articlePublished 17 Feb 2023

Broad Humoral Immunity Generated in Mice by a Formulation Composed by Two Antigens from Delta Variant of SARS-CoV-2

Authors: Yadira Lobaina, Rong Chen, Edith Suzarte, Panchao Ai, Vivian Huerta, Changyuan Tan, Liz Alvarez-Lajonchere, Yang Liling, Alexis Musacchio, Ricardo Silva, Gerardo Guillén, Jiang Zaixue, Ke Yang, Yasser Perera, Lisset Hermida

1Department of Genetics, Center for Genetic Engineering and Biotechnology of Cuba, Havana, Cuba; 2Department of Genetics, National Center for Scientific Research, Havana, Cuba; 3Department of Chemical Engineering, Zhejiang University of Technology, Hangzhou, China; 4Department of Laboratory Medicine, Dongguan Ninth People's Hospital, Guangdong, China; 5Department of Genetics, Center for Genetic Engineering and Biotechnology of Cuba, Beijing, China; 6Department of Pediatrics, Dongguan Institute of Pediatrics, Dongguan, China

Journal of Infectious Diseases & Therapy

Volume 11 · Issue 2 · Pages 1–7

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Study background: Due to the rapid development of new variants of SARS-CoV-2 virus, as well as the real threat of new Coronavirus zoonosis events, the development of a preventive vaccine with a broader scope of functionality is highly desirable. Previously, we reported the functionality of a nasal formulation based on the preparation of the nucleocapsid protein with the ODN-39M and combined with RBD, both antigens from Delta variant of SARS-CoV-2. This combination induces a cross reactive immunity in mucosal and systemic compartments until sarbecovirus level. In the present study, we explored the magnitude of the immunity generated in Balb/C mice by the same formulation, but adding alum as adjuvant, so as to enhance the humoral immunity against the two antigens. Methods: Animals were immunized with three doses of the bivalent formulation, administered by subcutaneous route. The humoral immunity was tested by ELISA and by a surrogate of viral neutralization test. The cell mediated immunity was also explored. Results: High levels of antibodies against both antigens (N and RBD) were obtained upon immunization. Additionally, the anti-RBD Abs with neutralizing capacity reacted against the three SARS-CoV-2 variants of RBD assayed, including omicron. At the same time, the Abs also recognized the nucleocapsid proteins from: SARSCoV- 1 and SARS-CoV-2 delta and omicron. Conclusion: Taken together, these results make the bivalent formulation tested, an attractive component of a pan Corona vaccine able to broaden the scope of humoral immunity against both antigens. This will be particularly important in the reinforcement of immunity from previously vaccinated and/or infected populations.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Journal of Infectious Diseases & Therapy.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Infectious Diseases & Therapy
  • SubjectInfectious Diseases
  • BylineArticles whose byline prints “Yadira Lobaina”
  • BylineArticles whose byline prints “Rong Chen”
  • BylineArticles whose byline prints “Edith Suzarte”
  • BylineArticles whose byline prints “Panchao Ai”
  • BylineArticles whose byline prints “Vivian Huerta”
  • BylineArticles whose byline prints “Changyuan Tan”
  • BylineArticles whose byline prints “Liz Alvarez-Lajonchere”
  • BylineArticles whose byline prints “Yang Liling”